EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Australian clinicians' perceptions of patients with very high risk of fracture

Christian M Girgis iD, Yoonah Choi, Peter R Ebeling

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16317 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Christian M Girgis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Osteoporotic Fractures, Osteoporosis, Bone Density Conservation Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

International osteoporosis guidelines have recommended treatment approaches based on fracture risk stratification, in particular, anabolic therapy for patients with very high risk (VHR) of fragility fracture.

Aim

To summarise Australian clinicians' perceptions of patients at VHR of fracture.

Methods

Australian clinicians invited to educational webinars on anabolic treatments for osteoporosis were surveyed in March and April 2021 about a typical patient they had most recently seen and identified as at VHR of fracture.

Results

Of the 268 clinician attendees who were invited to complete the post‐webinar surveys, 67 (25%) responded and permitted the publication of aggregated data. A typical patient perceived to have a VHR of fracture was a woman in her 80's, living at home, who had been diagnosed with osteoporosis between 5 and 10 years ago, and received treatment for 1–5 years' duration, most commonly denosumab. The patient frequently had a T ‐score below −3.0 SD (standard deviation), multiple fragility fractures and most commonly suffered a vertebral fracture in the past 12 months, whereas on an adequate regimen of osteoporosis medication. There was a mismatch between the patient being eligible for anabolic therapy (64.2%) and actually having been prescribed an anabolic treatment in the past (20.9%).

Conclusions

Australian clinicians' perceptions of patients with a VHR of fracture and the use of anabolic agents appear to be heavily influenced by local reimbursement criteria. The mismatch between patients deemed eligible for reimbursed anabolic therapy and those prescribed an anabolic agent suggests treatment inertia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoporotic FracturesOsteoporosisBone Density Conservation AgentsHumansAustraliaFemaleMaleRisk AssessmentAged, 80 and overSurveys and QuestionnairesAttitude of Health PersonnelMiddle AgedDenosumabAgedAnabolic Agents

Stichwörter der Autor:innen

anabolic agentsfracture riskosteoporosisperceptionsromosozumab

Substanzen

Bone Density Conservation AgentsDenosumabAnabolic Agents

Autor:innen und Institutionen

  • Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Evidencia Medical Communications Pty Ltd, Sydney, New South Wales, Australia.
  • Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.

ORCID-Profile: Christian M Girgis

Zitieren

APA

Girgis, C. M., Choi, Y., & Ebeling, P. R. (2024). Australian clinicians' perceptions of patients with very high risk of fracture. Internal Medicine Journal. https://doi.org/10.1111/imj.16317

Vancouver

Girgis CM, Choi Y, Ebeling PR. Australian clinicians' perceptions of patients with very high risk of fracture. Internal Medicine Journal. 2024. doi:10.1111/imj.16317

BibTeX
@article{Girgis2024,
  author = {Girgis, Christian M and Choi, Yoonah and Ebeling, Peter R},
  title = {Australian clinicians' perceptions of patients with very high risk of fracture},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16317}
}
Kostenlos starten →